United States
Bluejay Therapeutics, founded in 2020 and headquartered in the United States, is making significant strides in the Biotechnology, Health Care, and Pharmaceutical industries. The company is dedicated to developing innovative cures for infectious diseases, with a promising initial focus on the chronic HDV infection.
Under the evocative slogan, "Developing innovative cures for infectious diseases with the first target indication of chronic HDV infection," Bluejay Therapeutics has captured investor interest and confidence. The company recently secured a substantial $182.00M in a Series C investment round on 09 May 2024. Notable investors in this round include Novo Holdings, HBM Healthcare Investments, RA Capital Management, RiverVest, T. Rowe Price, Wellington Management, Octagon Capital Advisors, Unicorn Capital Partners, Frazier Life Sciences, and Arkin Bio Ventures.
With a clear mission and robust financial backing, Bluejay Therapeutics stands as a compelling option for potential investors looking to make impactful investments in the fight against infectious diseases.
